Proportion of patients treated with thrombolysis in a centralized versus a decentralized acute stroke care setting

Stroke

Volumn 43, Issue 5, 2012, Pages 1336-1340

  Lahr, Maarten M H ^a   Luijckx, Gert Jan ^a   Vroomen, Patrick C A J ^a   Van Der Zee, Durk Jouke ^b   Buskens, Erik ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Acute stroke; Implementation; Organizational model; Thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; COMMUNITY HOSPITAL; DRUG SAFETY; EMERGENCY HEALTH SERVICE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROIMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STROKE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FEMALE; FIBRINOLYTIC AGENTS; HEALTH SERVICES ACCESSIBILITY; HOSPITALS, COMMUNITY; HOSPITALS, GENERAL; HOSPITALS, URBAN; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84860220131     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.641795     Document Type: Article

References (29)

1. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, et al. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell National Acute Stroke Registry. Stroke. 2005;36:1232-1240. (Pubitemid 40798745)
4. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61:346-350. (Pubitemid 38327350)
5. Boode B, Welzen V, Franke C, van Oostenbrugge R. Estimating the number of stroke patients eligible for thrombolytic treatment if delay could be avoided. Cerebrovasc Dis. 2007;23:294-298. (Pubitemid 46425798)
6. Mikulik R, Bunt L, Hrdlicka D, Dusek L, Vaclavik D, Kryza J. Calling 911 in response to stroke: a nationwide study assessing definitive individual behavior. Stroke. 2008;39:1844-1849.
7. Weir NU, Buchan AM. A study of the workload and effectiveness of a comprehensive acute stroke service. J Neurol Neurosurg Psychiatry. 2005;76:863-865. (Pubitemid 40805820)
8. Foley N, Salter K, Teasell R. Specialized stroke services: a meta-analysis comparing three models of care. Cerebrovasc Dis. 2007;23:194-202. (Pubitemid 46239162)
9. Meretoja A, Roine RO, Kaste M, Linna M, Roine S, Juntunen M, et al. Effectiveness of primary and comprehensive stroke centers: PERFECT stroke: a nationwide observational study from Finland. Stroke. 2010;41:1102-1107.
10. Walter A, Seidel G, Thie A, Raspe H. Semi-intensive stroke unit versus conventional care in acute ischemic stroke or TIA-a prospective study in Germany. J Neurol Sci. 2009;287:131-137.
11. Price CI, Clement F, Gray J, Donaldson C, Ford GA. Systematic review of stroke thrombolysis service configuration. Expert Rev Neurother. 2009;9:211-233.
12. Verweij A, Sanderse C, Beer de J. Zijn er in Nederland verschillen naar regio? In: Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM. Nationaal Kompas Volksgezondheid/Bevolking 2011. Available at: http://www.nationaalkompas.nl. Accessed November 29, 2011.
13. Uyttenboogaart M, Schrijvers EM, Vroomen PC, De Keyser J, Luijckx GJ. Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience. Age Ageing. 2007;36:577-579. (Pubitemid 47558837)
14. Ford GA, Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg PJ, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke. 2010;41:2568-2574.
15. Tirschwell DL, Longstreth WT Jr, Becker KJ, Gammans RE Sr, Sabounjian LA, Hamilton S, et al. Shortening the NIH Stroke scale for use in the prehospital setting. Stroke. 2002;33:2801-2806. (Pubitemid 35462847)
16. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. (Pubitemid 46138121)
17. Dutch Stroke Guideline 'Diagnostics, treatment, and care for stroke patients.' Dutch Institute for Healthcare Improvement CBO. 2008. Available at: http://www.cbo.nl/Downloads/218/rl-beroerte-09.pdf. Accessed November 29, 2011.
18. Demaerschalk BM, Bobrow BJ, Paulsen M, Phoenix Operation Stroke Executive Committee. Development of a metropolitan matrix of primary stroke centers: the Phoenix experience. Stroke. 2008;39:1246-1253. (Pubitemid 351440698)
19. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM, Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke. 2003;34:799-800.
20. Rymer MM, Thurtchley D, Summers D, America Brain and Stroke Institute Stroke Team. Expanded modes of tissue plasminogen activator delivery in a comprehensive stroke center increases regional acute stroke interventions. Stroke. 2003;34:e58-e60.
21. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke. 2001;32:1832-1840.
22. Albright KC, Schott TC, Jafari N, Wohlford-Wessels MP, Finnerty EP, Jacoby MR. Tissue plasminogen activator use: evaluation and initial management of ischemic stroke from an Iowa hospital perspective. J Stroke Cerebrovasc Dis. 2005;14:127-135. (Pubitemid 40637605)
23. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001;58:2009-2013. (Pubitemid 33143979)
24. Leira EC, Pary JK, Davis PH, Grimsman KJ, Adams HP Jr. Slow progressive acceptance of intravenous thrombolysis for patients with stroke by rural primary care physicians. Arch Neurol. 2007;64:518-521. (Pubitemid 46603620)
25. Wojner-Alexandrov AW, Alexandrov AV, Rodriguez D, Persse D, Grotta JC. Houston paramedic and emergency stroke treatment and outcomes study (HoPSTO). Stroke. 2005;36:1512-1518. (Pubitemid 40967522)
26. van Wijngaarden JD, Dirks M, Dippel DW, Minkman M, Niessen LW. Towards effective and efficient care pathways: thrombolysis in acute ischaemic stroke. QJM. 2006;99:267-272.
27. Dirks M, Niessen LW, van Wijngaarden JD, Koudstaal PJ, Franke CL, van Oostenbrugge RJ, et al. Promoting thrombolysis in acute ischemic stroke. Stroke. 2011;42:1325-1330.
28. Lahr MM, Luijckx GJ, Vroomen PC, van der Zee DJ, Buskens E. Promoting thrombolysis in acute ischemic stroke. Stroke. 2011;42:e411.
29. Stahl JE, Furie KL, Gleason S, Gazelle GS. Stroke: Effect of implementing an evaluation and treatment protocol compliant with NINDS recommendations. Radiology. 2003;228:659-668. (Pubitemid 37025472)